D Aletaha

Summary

Affiliation: Medical University of Vienna
Country: Austria

Publications

  1. pmc Value of self-performed joint counts in rheumatoid arthritis patients near remission
    Helga Radner
    Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Waehringerguertel 18 20, Vienna, 1090, Austria
    Arthritis Res Ther 14:R61. 2012
  2. doi Rheumatoid factor determines structural progression of rheumatoid arthritis dependent and independent of disease activity
    Daniel Aletaha
    Division of Rheumatology, Department of Medicine 3, Medical University Vienna, and Second Department of Medicine, Hietzing Hospital, Vienna, Austria
    Ann Rheum Dis 72:875-80. 2013
  3. doi Rituximab dissociates the tight link between disease activity and joint damage in rheumatoid arthritis patients
    Daniel Aletaha
    Department of Medicine 3, Medical University of Vienna, Vienna, Austria
    Ann Rheum Dis 72:7-12. 2013
  4. doi Serological changes in the course of traditional and biological disease modifying therapy of rheumatoid arthritis
    Christoph Böhler
    Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Waehringer Guertel 18 20, Vienna 1090, Austria
    Ann Rheum Dis 72:241-4. 2013
  5. pmc Nothing lasts forever - a critical look at sustained remission
    Daniel Aletaha
    Division of Rheumatology, Medical University of Vienna, Wahringer Gurtel 18 20, 1090 Vienna, Austria
    Arthritis Res Ther 14:116. 2012
  6. doi Near misses of ACR/EULAR criteria for remission: effects of patient global assessment in Boolean and index-based definitions
    Paul Studenic
    Division of Rheumatology, Department of Internal Medicine 3, Medical University Vienna, 1090 Vienna, Austria
    Ann Rheum Dis 71:1702-5. 2012
  7. doi Definition of treatment response in rheumatoid arthritis based on the simplified and the clinical disease activity index
    Daniel Aletaha
    Medical University of Vienna, Department of Rheumatology, Spitalgasse 23, 1090 Vienna, Austria
    Ann Rheum Dis 71:1190-6. 2012
  8. pmc Disease activity level, remission and response in established rheumatoid arthritis: performance of various criteria sets in an observational cohort, treated with anti-TNF agents
    Anders Gülfe
    Dept of Rheumatology, Lund University Hospital, Lund, Sweden
    BMC Musculoskelet Disord 10:41. 2009
  9. pmc Remission by composite scores in rheumatoid arthritis: are ankles and feet important?
    Theresa Kapral
    Department of Rheumatology, Medical University of Vienna, Waehringer Guertel 18 20, 1090 Vienna, Austria
    Arthritis Res Ther 9:R72. 2007
  10. pmc Developments in the clinical understanding of rheumatoid arthritis
    Josef S Smolen
    Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, and 2nd Department of Medicine, Hietzing Hospital, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Arthritis Res Ther 11:204. 2009

Collaborators

Detail Information

Publications95

  1. pmc Value of self-performed joint counts in rheumatoid arthritis patients near remission
    Helga Radner
    Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Waehringerguertel 18 20, Vienna, 1090, Austria
    Arthritis Res Ther 14:R61. 2012
    ..To determine the validity and reliability of patients' self-performed joint counts compared to joint counts by professional assessors in rheumatoid arthritis (RA) patients in different disease activity states...
  2. doi Rheumatoid factor determines structural progression of rheumatoid arthritis dependent and independent of disease activity
    Daniel Aletaha
    Division of Rheumatology, Department of Medicine 3, Medical University Vienna, and Second Department of Medicine, Hietzing Hospital, Vienna, Austria
    Ann Rheum Dis 72:875-80. 2013
    ..RF is associated with joint destruction, but the role of disease activity as a potential mediator of these effects has not been clearly elucidated yet...
  3. doi Rituximab dissociates the tight link between disease activity and joint damage in rheumatoid arthritis patients
    Daniel Aletaha
    Department of Medicine 3, Medical University of Vienna, Vienna, Austria
    Ann Rheum Dis 72:7-12. 2013
    ..It is hitherto unknown if this may also be true for therapies targeting B-cells. We thus evaluated if rituximab (RTX) therapy inhibits joint damage irrespective of its effects on disease activity...
  4. doi Serological changes in the course of traditional and biological disease modifying therapy of rheumatoid arthritis
    Christoph Böhler
    Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Waehringer Guertel 18 20, Vienna 1090, Austria
    Ann Rheum Dis 72:241-4. 2013
    ..To investigate changes of rheumatoid factor (RF) and antibodies against citrullinated peptides (ACPA) during therapy with disease modifying antirheumatic drugs...
  5. pmc Nothing lasts forever - a critical look at sustained remission
    Daniel Aletaha
    Division of Rheumatology, Medical University of Vienna, Wahringer Gurtel 18 20, 1090 Vienna, Austria
    Arthritis Res Ther 14:116. 2012
    ..A study by Prince and colleagues gives insights into this question, and raises some other questions for the future...
  6. doi Near misses of ACR/EULAR criteria for remission: effects of patient global assessment in Boolean and index-based definitions
    Paul Studenic
    Division of Rheumatology, Department of Internal Medicine 3, Medical University Vienna, 1090 Vienna, Austria
    Ann Rheum Dis 71:1702-5. 2012
    ..The American College of Rheumatology/European League Against Rheumatism remission criteria for rheumatoid arthritis (RA) have been published recently...
  7. doi Definition of treatment response in rheumatoid arthritis based on the simplified and the clinical disease activity index
    Daniel Aletaha
    Medical University of Vienna, Department of Rheumatology, Spitalgasse 23, 1090 Vienna, Austria
    Ann Rheum Dis 71:1190-6. 2012
    ..To date, no validated response definitions for the SDAI and CDAI are available...
  8. pmc Disease activity level, remission and response in established rheumatoid arthritis: performance of various criteria sets in an observational cohort, treated with anti-TNF agents
    Anders Gülfe
    Dept of Rheumatology, Lund University Hospital, Lund, Sweden
    BMC Musculoskelet Disord 10:41. 2009
    ..We therefore wanted to compare the performance of the DAS28, SDAI and CDAI activity indices, their activity states, their response criteria, and also compare with the ACR response criteria in an observational clinical setting...
  9. pmc Remission by composite scores in rheumatoid arthritis: are ankles and feet important?
    Theresa Kapral
    Department of Rheumatology, Medical University of Vienna, Waehringer Guertel 18 20, 1090 Vienna, Austria
    Arthritis Res Ther 9:R72. 2007
    ..However, reduced joint counts are appropriate and valid tools for formal disease activity assessment, such as done in composite indices...
  10. pmc Developments in the clinical understanding of rheumatoid arthritis
    Josef S Smolen
    Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, and 2nd Department of Medicine, Hietzing Hospital, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Arthritis Res Ther 11:204. 2009
    ..Finally, with the advent of novel therapies, remission has become a reality and the treatment algorithms encompassing all of the above-mentioned aspects will allow us to achieve the rigorous aspirations of today and tomorrow...
  11. doi Rheumatoid arthritis joint progression in sustained remission is determined by disease activity levels preceding the period of radiographic assessment
    D Aletaha
    Division of Rheumatology, Medical University of Vienna, Vienna, Austria
    Arthritis Rheum 60:1242-9. 2009
    ..The aim of this study was to evaluate whether there is a latency in the effect of disease activity on radiographic progression in patients with RA...
  12. doi The use of data from early arthritis clinics for clinical research
    Daniel Aletaha
    Division of Rheumatology, Department of Internal Medicine 3, Medical University of Vienna, Vienna, Austria
    Best Pract Res Clin Rheumatol 23:117-23. 2009
    ....
  13. pmc Perception of improvement in patients with rheumatoid arthritis varies with disease activity levels at baseline
    D Aletaha
    Department of Internal Medicine 3, Medical University of Vienna, Vienna, Austria
    Arthritis Rheum 61:313-20. 2009
    ..To analyze the minimum clinically important improvement (MCII) of disease activity measures in rheumatoid arthritis (RA) using patient-derived anchors, and to assess whether criteria for improvement differ with baseline disease activity...
  14. ncbi The perception of rheumatoid arthritis core set measures by rheumatologists. Results of a survey
    D Aletaha
    Department of Rheumatology, Internal Medicine III, Medical University of Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Rheumatology (Oxford) 45:1133-9. 2006
    ..To investigate the perception of values of individual core set measures by rheumatologists, and how it differs across measures and across physicians...
  15. ncbi Measuring function in rheumatoid arthritis: Identifying reversible and irreversible components
    Daniel Aletaha
    National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, Maryland, USA
    Arthritis Rheum 54:2784-92. 2006
    ..We aimed to dissect these two components of functional limitation in rheumatoid arthritis (RA) by using the disability index of the Health Assessment Questionnaire (HAQ) as the measure of function...
  16. ncbi Remission of rheumatoid arthritis: should we care about definitions?
    D Aletaha
    Department of Rheumatology, Medical University of Vienna, Vienna, Austria
    Clin Exp Rheumatol 24:S-45-51. 2006
    ..All composite indices seem to perform similarly well as tests for remission using expert judgments as the gold standard...
  17. doi Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations
    D Aletaha
    Division of Rheumatology, Medical University of Vienna, Vienna, Austria
    Ann Rheum Dis 67:1360-4. 2008
    ..To make recommendations on how to report disease activity in clinical trials of rheumatoid arthritis (RA) endorsed by the European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR)...
  18. doi [Rheumatoid arthritis. Target outcome for treatment]
    D Aletaha
    Klinische Abteilung für Rheumatologie, Klinik für Innere Medizin 3, Medizinische Universität Wien, Wahringer Gurtel 18 20, 1090, Wien, Osterreich
    Z Rheumatol 68:10-5. 2009
    ..Standardised intensive therapeutic strategies and algorithms should form the basis for the administration of anti-rheumatic medication...
  19. ncbi The health assessment questionnaire in routine clinical practice
    Daniel Aletaha
    Division of Rheumatology, Medical University of Vienna, Vienna, Austria
    Nat Clin Pract Rheumatol 3:122-3. 2007
  20. doi Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations
    D Aletaha
    Medical University of Vienna, Vienna, Austria
    Arthritis Rheum 59:1371-7. 2008
    ..To make recommendations on how to report disease activity in clinical trials of rheumatoid arthritis (RA) endorsed by the European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR)...
  21. ncbi Treatment-related improvement in physical function varies with duration of rheumatoid arthritis: a pooled analysis of clinical trial results
    D Aletaha
    Department of Rheumatology, Internal Medicine III, Medical University of Vienna, Austria
    Ann Rheum Dis 67:238-43. 2008
    ....
  22. doi Methods of deriving EULAR/ACR recommendations on reporting disease activity in clinical trials of patients with rheumatoid arthritis
    T Karonitsch
    Division of Rheumatology, Medical University of Vienna, Vienna, Austria
    Ann Rheum Dis 67:1365-73. 2008
    ....
  23. doi The importance of reporting disease activity states in rheumatoid arthritis clinical trials
    Daniel Aletaha
    Medical University of Vienna, Vienna, Austria
    Arthritis Rheum 58:2622-31. 2008
    ..g., American College of Rheumatology [ACR] responder status) with the value of evaluating absolute disease activity states (e.g., remission)...
  24. ncbi The definition and measurement of disease modification in inflammatory rheumatic diseases
    Daniel Aletaha
    Department of Rheumatology, Internal Medicine III, Medical University of Vienna, Vienna, Austria
    Rheum Dis Clin North Am 32:9-44, vii. 2006
    ....
  25. doi Rheumatoid arthritis near remission: clinical rather than laboratory inflammation is associated with radiographic progression
    Daniel Aletaha
    Department of Medicine 3, Division of Rheumatology, Medical University Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Ann Rheum Dis 70:1975-80. 2011
    ..In general, both contribute to the progression of joint damage, but the relevance of residual inflammation in patients near remission is unclear...
  26. doi Physical disability in rheumatoid arthritis is associated with cartilage damage rather than bone destruction
    Daniel Aletaha
    Department of Internal Medicine 3, Division of Rheumatology, Medical University Vienna, Waehringer Guertel 18 20, 1090 Vienna, Austria
    Ann Rheum Dis 70:733-9. 2011
    ..It is currently unclear to which extent these components affect irreversible functional disability. The aim of the present work was to determine these contributions...
  27. pmc Treating rheumatic patients with a malignancy
    Katarzyna Elandt
    Division of Oncology, Department of Internal Medicine 1, Medical University Vienna, Austria
    Arthritis Res Ther 13:223. 2011
    ..In conclusion, the decision to treat a patient with a history of cancer immunosuppressively should be shared by the rheumatologist and the oncologist. Once the decision is established, such patients need intensive and close monitoring...
  28. ncbi Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states
    Daniel Aletaha
    Department of Rheumatology, Medical University of Vienna, Vienna, Austria
    Arthritis Rheum 52:2625-36. 2005
    ..We aimed to reevaluate or to define such criteria for the Disease Activity Score in 28 joints (DAS28) and the Simplified Disease Activity Index (SDAI)...
  29. doi Joint damage in rheumatoid arthritis progresses in remission according to the Disease Activity Score in 28 joints and is driven by residual swollen joints
    Daniel Aletaha
    Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Wahringer Gurtel 18 20, A 1090 Vienna, Austria
    Arthritis Rheum 63:3702-11. 2011
    ..This study was undertaken to investigate the significance of residual inflammation in remission in relation to radiographic progression...
  30. pmc Attitudes to early rheumatoid arthritis: changing patterns. Results of a survey
    D Aletaha
    Division of Rheumatology, Department of Internal Medicine III, University of Vienna, Vienna General Hospital, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Ann Rheum Dis 63:1269-75. 2004
    ..To determine if rheumatologists have changed their views on diagnosis and treatment of early rheumatoid arthritis (RA)...
  31. doi The Simplified Disease Activity Index and Clinical Disease Activity Index to monitor patients in standard clinical care
    Daniel Aletaha
    Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Rheum Dis Clin North Am 35:759-72, viii. 2009
    ..Moreover, remission criteria of CDAI and SDAI are currently the most stringent...
  32. ncbi The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis
    D Aletaha
    Department of Rheumatology, Medical University of Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Clin Exp Rheumatol 23:S100-8. 2005
    ....
  33. ncbi [Measuring disease activity for rheumatoid arthritis]
    D Aletaha
    Klinische Abt für Rheumatologie, Universitätsklinik für Innere Medizin III, Wien
    Z Rheumatol 65:93-6, 98-102. 2006
    ..This will further improve our ability to care for patients with RA consequently...
  34. doi Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade
    J S Smolen
    Department of Internal Medicine III, Medical University of Vienna, Austria
    Ann Rheum Dis 68:823-7. 2009
    ..To examine the association of radiographic progression and disease activity states in patients with rheumatoid arthritis (RA) treated with methotrexate with or without infliximab...
  35. pmc Survival and effectiveness of leflunomide compared with methotrexate and sulfasalazine in rheumatoid arthritis: a matched observational study
    D Aletaha
    Division of Rheumatology, Department of Internal Medicine III, University of Vienna, Austria
    Ann Rheum Dis 62:944-51. 2003
    ..To determine the survival and clinical effectiveness of leflunomide (LEF) compared with methotrexate (MTX) and sulfasalazine (SSZ) for RA in an observational study...
  36. pmc Step-up combination versus switching of non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a retrospective observational study
    M Schoels
    Second Department of Medicine, Hietzing Hospital, Vienna, Austria
    Ann Rheum Dis 66:1059-65. 2007
    ..In rheumatoid arthritis (RA), treatment with disease-modifying antirheumatic drugs (DMARDs) frequently needs to be changed because of insufficient effectiveness...
  37. ncbi Very recent onset rheumatoid arthritis: clinical and serological patient characteristics associated with radiographic progression over the first years of disease
    K P Machold
    Department of Rheumatology, Medical University of Vienna, Vienna, Austria
    Rheumatology (Oxford) 46:342-9. 2007
    ..This study was performed to determine the frequency of erosive arthritis and the pace of radiological progression in an inception cohort of patients with very early RA (<or=3 months after onset of symptoms)...
  38. ncbi DMARD use in early rheumatoid arthritis. Lessons from observations in patients with established disease
    D Aletaha
    Division of Rheumatology, Department of Internal Medicine III, University of Vienna, Vienna General Hospital, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Clin Exp Rheumatol 21:S169-73. 2003
    ..By contrast to changes in DMARD usage, survey data show neither a shortening of referral time nor a change in the approach to diagnose early RA. These data indicate a need for more dissemination of the early arthritis concept...
  39. pmc Practical progress in realisation of early diagnosis and treatment of patients with suspected rheumatoid arthritis: results from two matched questionnaires within three years
    D Aletaha
    Division of Rheumatology, Department of Internal Medicine III, University of Vienna, Austria
    Ann Rheum Dis 61:630-4. 2002
    ..This survey focuses on the individual definitions and treatment modalities of rheumatologists, and aims at determining the practical realisation of these concepts...
  40. pmc Duration of rheumatoid arthritis influences the degree of functional improvement in clinical trials
    D Aletaha
    Intramural Research Program, NIAMS, National Institutes of Health, Bethesda, MD 20892, USA
    Ann Rheum Dis 65:227-33. 2006
    ..Functional limitation incorporates both activity and damage. Because irreversible damage increases over time, the HAQ may be less likely to show improvement in late than in early rheumatoid arthritis...
  41. ncbi What should be our treatment goal in rheumatoid arthritis today?
    J S Smolen
    Department of Rheumatology, Medical University of Vienna Second Department of Medicine, Lainz Hospital, Vienna, Austria
    Clin Exp Rheumatol 24:S-7-13. 2006
    ....
  42. ncbi Assessing remission in clinical practice
    M Mierau
    2nd Department of Medicine, Hietzing Hospital, Vienna, Austria
    Rheumatology (Oxford) 46:975-9. 2007
    ..We aimed at evaluating sustained remission in a large cohort of patients followed prospectively in clinical practice and to evaluate available instruments to define remission for their stringency in defining this state...
  43. doi Progression of radiographic joint damage in rheumatoid arthritis: independence of erosions and joint space narrowing
    J S Smolen
    Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Waehringer Guertel 18 20, A 1090, Vienna, Austria
    Ann Rheum Dis 68:1535-40. 2009
    ....
  44. ncbi [Activity-score based therapy in rheumatoid arthritis]
    K Machold
    Klinische Abt für Rheumatologie, Universitätsklinik für Innere Medizin III, Wien
    Z Rheumatol 65:124, 126-30. 2006
    ..This review presents evidence for the benefits of the application disease activity scores in clinical routine...
  45. ncbi The use of databases for quality assessment in rheumatoid arthritis
    T A Stamm
    Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria
    Clin Exp Rheumatol 25:82-5. 2007
    ....
  46. ncbi The burden of rheumatoid arthritis and access to treatment: a medical overview
    J Smolen
    Division of Rheumatology, Internal Medicine III, Medical University of Vienna, Vienna, Austria
    Eur J Health Econ 8:S39-47. 2008
    ..Therapeutic outcome can be predicted by clinical means...
  47. ncbi Glucocorticoid treatment in rheumatoid arthritis: low-dose therapy does not reduce responsiveness to higher doses
    J Wolf
    Second Department of Medicine, Hietzing Hospital, Vienna, Austria
    Clin Exp Rheumatol 26:113-6. 2008
    ..Since low dose GC has been suggested to confer resistance to higher doses, we aimed to assess if resistance was detectable on the clinical level in patients with active RA...
  48. ncbi The rheumatoid arthritis patient in the clinic: comparing more than 1,300 consecutive DMARD courses
    D Aletaha
    Division of Rheumatology, Department of Internal Medicine III, University of Vienna, Vienna, Austria
    Rheumatology (Oxford) 41:1367-74. 2002
    ..This study aimed to reveal treatment patterns with traditional DMARDs and their changes during the two decades before the recent introduction of new DMARDs...
  49. pmc Toxicity profiles of traditional disease modifying antirheumatic drugs for rheumatoid arthritis
    D Aletaha
    Division of Rheumatology, Department of Internal Medicine III, University of Vienna, Austria
    Ann Rheum Dis 62:482-6. 2003
    ..The progression of rheumatoid arthritis (RA) can be retarded or halted by disease modifying antirheumatic drugs (DMARDs). Next to inefficacy, toxicity limits their use...
  50. doi The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: methodological report phase I
    Julia Funovits
    Division of Rheumatology, Medical University Vienna, Waehringer Guertel 18 20, Vienna, Austria
    Ann Rheum Dis 69:1589-95. 2010
    ....
  51. doi Application of the DAREA/DAPSA score for assessment of disease activity in psoriatic arthritis
    Monika Schoels
    Second Department of Medicine, Hietzing Hospital, Vienna, Austria
    Ann Rheum Dis 69:1441-7. 2010
    ..Therefore, the reliability and validity of DAREA (for 'Disease Activity index for REactive Arthritis'), which was originally developed for reactive arthritis and employs a 66/68 joint count, was tested in patients with PsA...
  52. doi Estimation of a numerical value for joint damage-related physical disability in rheumatoid arthritis clinical trials
    Josef S Smolen
    Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna General Hospital, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Ann Rheum Dis 69:1058-64. 2010
    ..Joint damage is an important outcome in trials of rheumatoid arthritis (RA), usually assessed by Total Sharp Score (TSS). It is currently unknown how it translates numerically into disability by the Health Assessment Questionnaire (HAQ)...
  53. ncbi Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients
    Daniel Aletaha
    Medical University of Vienna, Vienna, Austria
    Arthritis Rheum 56:3226-35. 2007
    ..To assess whether disease activity levels at treatment initiation or during the first 3 months of therapy predict disease activity at 1 year after treatment initiation...
  54. doi Does damage cause inflammation? Revisiting the link between joint damage and inflammation
    J S Smolen
    Division of Rheumatology, Department of Internal Medicine 3, Medical University of Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Ann Rheum Dis 68:159-62. 2009
    ..However, the clinical evidence for this relationship is still to be provided as proof of the concept...
  55. ncbi [Clinical outcome measures in hand- and finger joint osteoarthritis from the patient perspective]
    T Stamm
    Abt für Rheumatologie, Klinik fur Innere Medizin III, Medizinische Universität Wien
    Z Rheumatol 65:139-43. 2006
    ..Some instruments lack reliability because standardized protocols for measurement have not yet been developed...
  56. ncbi Challenges of predicting treatment response in patients with rheumatoid arthritis
    Josef S Smolen
    Division of Rheumatology, Medical University of Vienna, Vienna, Austria
    Nat Clin Pract Rheumatol 1:62-3. 2005
  57. doi Impact of comorbidity on physical function in patients with rheumatoid arthritis
    Helga Radner
    Division of Rheumatology, Department of Internal Medicine 3, Medical University Vienna, Waehringer Guertel 18 20, 1090 Vienna, Austria
    Ann Rheum Dis 69:536-41. 2010
    ..Physical disability is a main outcome in rheumatoid arthritis (RA) which tends to increase with comorbidities. However, the extent to which comorbidities contribute to the multifactorial process of disability has not been investigated...
  58. doi Evaluation of the appropriateness of composite disease activity measures for assessment of psoriatic arthritis
    Valerie P Nell-Duxneuner
    Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Ann Rheum Dis 69:546-9. 2010
    ..Specific composite indices assessing disease activity in psoriatic arthritis (PsA) have not yet been sufficiently validated. The objective of this study was to identify instruments best reflecting disease activity in PsA...
  59. ncbi Threats to validity of observational studies on disease-modifying antirheumatic drug therapies for rheumatoid arthritis: new aspects after the fall of the pyramid and the rise of new therapeutics
    Daniel Aletaha
    Division of Rheumatology, Department of Internal Medicine III, University of Vienna, Vienna General Hospital, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Curr Rheumatol Rep 5:409-12. 2003
  60. ncbi The assessment of disease activity in rheumatoid arthritis
    Josef S Smolen
    Division of Rheumatology, Medical University of Vienna, and Hietzing Hospital, Vienna, Austria
    Clin Exp Rheumatol 28:S18-27. 2010
    ..The latest developments in the field are discussed and will help to identify patients who can benefit most from today's opportunities of pharmacotherapy, allowing optimization of patient care...
  61. doi Comorbidity affects all domains of physical function and quality of life in patients with rheumatoid arthritis
    Helga Radner
    Department of Internal Medicine 3, Medical University Vienna, 1090 Vienna, Austria
    Rheumatology (Oxford) 50:381-8. 2011
    ..In this study, we investigated the impact of comorbidities on individual activities of daily living, and other aspects of quality of live in patients with RA...
  62. doi Response of elderly patients with rheumatoid arthritis to methotrexate or TNF inhibitors compared with younger patients
    Marcus D Köller
    Department of Rheumatology Internal Medicine III, General Hospital Medical University of Vienna, Vienna, Austria
    Rheumatology (Oxford) 48:1575-80. 2009
    ..To compare the efficacy of MTX and MTX+TNF inhibitors (TNFis) in elderly patients with RA with that in patients of younger age...
  63. ncbi Depletion of endothelial progenitor cells in the peripheral blood of patients with rheumatoid arthritis
    Johannes Grisar
    Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Circulation 111:204-11. 2005
    ..Because the quantity of endothelial progenitor cells (EPCs) in the peripheral blood is correlated inversely with cardiovascular risk, we studied whether such abnormalities could also be observed in patients with RA...
  64. ncbi Power Doppler sonography and pulse-inversion harmonic imaging in evaluation of rheumatoid arthritis synovitis
    Claudia Schueller-Weidekamm
    Department of Diagnostic Radiology, Medical University of Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    AJR Am J Roentgenol 188:504-8. 2007
    ....
  65. pmc Endothelial progenitor cells in active rheumatoid arthritis: effects of tumour necrosis factor and glucocorticoid therapy
    Johannes Grisar
    Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Ann Rheum Dis 66:1284-8. 2007
    ....
  66. doi Strengths and limitations of a systematic review on DMARDs for rheumatoid arthritis
    Josef S Smolen
    Division of Rheumatology, Medical University of Vienna, Vienna, Austria
    Nat Clin Pract Rheumatol 4:296-7. 2008
  67. pmc The need for prognosticators in rheumatoid arthritis. Biological and clinical markers: where are we now?
    Josef S Smolen
    Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Arthritis Res Ther 10:208. 2008
    ..The analysis suggests the search for better markers to predict outcomes and therapeutic responsiveness in rheumatoid arthritis needs to be intensified...
  68. ncbi Mapping hand functioning in hand osteoarthritis: comparing self-report instruments with a comprehensive hand function test
    Tanja Stamm
    Vienna Medical University, Vienna, Austria
    Arthritis Rheum 57:1230-7. 2007
    ..To determine which self-report instruments best explain hand functioning measured by a generic comprehensive hand function test...
  69. pmc The public neglect of rheumatic diseases: insights from analyses of attendees in a musculoskeletal disease awareness activity
    Klaus P Machold
    Department of Rheumatology, Internal Medicine III, Medical University of Vienna, Vienna, Austria
    Ann Rheum Dis 66:697-9. 2007
    ..To obtain data on the care received by individuals counselled during a public health awareness campaign on painful musculoskeletal conditions (MSC)...
  70. ncbi Concepts important to patients with psoriatic arthritis are not adequately covered by standard measures of functioning
    Tanja A Stamm
    Department of Internal Medicine III, Division of Rheumatology, Vienna Medical University, Vienna, Austria
    Arthritis Rheum 57:487-94. 2007
    ..To explore whether the concepts important to patients with psoriatic arthritis (PsA) are covered by self-report instruments assessing functioning...
  71. ncbi Advances in anti-inflammatory therapy
    D Aletaha
    Division of Rheumatology, Department of Internal Medicine III, University of Vienna, Wahringer Gurtel 18 20, A 1090 Vienna
    Acta Med Austriaca 29:1-6. 2002
    ..NSAIDs have the potential to cause adverse events in the GI tract. Therapy with histamine antagonists or sucralfate did not reduce the patients' rate of gastrointestinal adverse events...
  72. doi 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative
    Daniel Aletaha
    Medical University of Vienna, Vienna, Austria
    Arthritis Rheum 62:2569-81. 2010
    ..This work was undertaken to develop new classification criteria for RA...
  73. pmc EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs
    Josef S Smolen
    Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Ann Rheum Dis 69:964-75. 2010
    ....
  74. pmc Treating rheumatoid arthritis to target: recommendations of an international task force
    Josef S Smolen
    Department of Internal Medicine 3, Division of Rheumatology, Medical University of Vienna, Waehringer Guertel 18 20, Vienna, Austria
    Ann Rheum Dis 69:631-7. 2010
    ..Aiming at therapeutic targets has reduced the risk of organ failure in many diseases such as diabetes or hypertension. Such targets have not been defined for rheumatoid arthritis (RA)...
  75. ncbi Therapeutic strategies in early rheumatoid arthritis
    Josef S Smolen
    Division of Rheumatology, Internal Medicine III, Medical University of Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Best Pract Res Clin Rheumatol 19:163-77. 2005
    ..Whether a 'window of opportunity' exists during which effective therapy might lead to cure is still an open issue and will be the focus of clinical trials in the near future...
  76. doi Follow-up standards and treatment targets in rheumatoid arthritis: results of a questionnaire at the EULAR 2008
    Monika Schoels
    2nd Department of Medicine, Centre for Rheumatic Diseases, Hietzing Hospital, Vienna, Austria
    Ann Rheum Dis 69:575-8. 2010
    ..The importance of tight control and early treatment, rapidly altered if goals are not achieved, is supported by evidence. However, it is unknown to what extent these insights are accepted by practitioners in clinical practice...
  77. doi Activity assessments in rheumatoid arthritis
    Josef S Smolen
    Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Austria
    Curr Opin Rheumatol 20:306-13. 2008
    ..the importance of assessing disease activity in general, aiming for significant improvement particularly low disease activity and remission, and the value of employing simplified instruments toward this end in rheumatoid arthritis..
  78. ncbi The challenge of following process, damage, and function in patients with rheumatoid arthritis in clinical care
    Josef S Smolen
    Department of Rheumatology, Internal Medicine III, Vienna General Hospital, University of Vienna, Wolkersbergenstrasse 1, Vienna A 1130, Austria
    Curr Rheumatol Rep 5:336-40. 2003
  79. ncbi Pro-inflammatory cytokines in rheumatoid arthritis: pathogenetic and therapeutic aspects
    Josef S Smolen
    Division of Rheumatology, Internal Medicine III, Medical University of Vienna, Austria
    Clin Rev Allergy Immunol 28:239-48. 2005
    ....
  80. doi Quantitative and qualitative deficiencies of regulatory T cells in patients with systemic lupus erythematosus (SLE)
    Michael Bonelli
    Division of Rheumatology, Internal Medicine III, General Hospital of Vienna, Medical University of Vienna, Waehringer Guertel 18 20, A 1090 Wien, Austria
    Int Immunol 20:861-8. 2008
    ..Our data describe quantitative and qualitative defects of Treg in SLE patients. These deficiencies might contribute to the breakdown of self-tolerance and the development of the autoimmune response in SLE patients...
  81. ncbi Early rheumatoid arthritis
    Klaus P Machold
    Department of Rheumatology, Internal Medicine III, Vienna Medical University, Austria
    Curr Opin Rheumatol 18:282-8. 2006
    ..This review provides novel and updated information on pathogenesis, referral, and clinical characteristics as well as therapeutic approaches in early rheumatoid arthritis...
  82. pmc Methotrexate in rheumatoid arthritis is frequently effective, even if re-employed after a previous failure
    Theresa Kapral
    Department of Rheumatology, Internal Medicine III, Medical University of Vienna, Vienna, Austria
    Arthritis Res Ther 8:R46. 2006
    ..Re-employment of MTX despite prior inefficacy, but not re-employment of other DMARDs, is an effective therapeutic option, especially in those patients in whom the methotrexate dose of the original course was low...
  83. ncbi Superior efficacy of combination therapy for rheumatoid arthritis: fact or fiction?
    Josef S Smolen
    Medical University of Vienna and Lainz Hospital, Vienna, Austria
    Arthritis Rheum 52:2975-83. 2005
  84. ncbi New therapies for treatment of rheumatoid arthritis
    Josef S Smolen
    Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria
    Lancet 370:1861-74. 2007
    ..Novel therapeutic strategies in conjunction with optimised disease assessment for better treatment of rheumatoid arthritis and an outlook into potential future targets are also presented...
  85. ncbi The Simplified Disease Activity Index (SDAI) and Clinical Disease Activity Index (CDAI) to monitor patients in standard clinical care
    Daniel Aletaha
    Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Best Pract Res Clin Rheumatol 21:663-75. 2007
    ....
  86. ncbi The need for new classification criteria for rheumatoid arthritis
    Daniel Aletaha
    Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna General Hospital, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Arthritis Rheum 52:3333-6. 2005
  87. ncbi Cytogenetic risk groups in acute myeloblastic leukaemia differ greatly in their semi-solid colony growth
    L Ohler
    Department of Internal Medicine I, University of Vienna, Vienna, Austria
    Br J Haematol 113:120-5. 2001
    ..0004). Our data suggest that the growth potential of the leukaemic clone seems to be critically influenced by the molecular changes emerging from chromosomal abnormalities...
  88. pmc Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score
    Daniel Aletaha
    Department of Rheumatology, Medical University of Vienna, Vienna, Austria
    Arthritis Res Ther 7:R796-806. 2005
    ..e. the sum of tender and swollen joint counts [28 joints] and patient and physician global assessments [in cm]) - would have comparable validity in clinical cohorts...
  89. pmc Evidence for treating rheumatoid arthritis to target: results of a systematic literature search
    Monika Schoels
    Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Waehringer Guertel 18 20, Vienna, Austria
    Ann Rheum Dis 69:638-43. 2010
    ..To summarise existing evidence on a target oriented approach for rheumatoid arthritis (RA) treatment...
  90. pmc Pooled indices to measure rheumatoid arthritis activity: a good reflection of the physician's mind?
    Daniel Aletaha
    National Institutes of Arthritis, Musculoskeletal, and Skin Diseases, National Institutes of Health, Bethesda, Maryland, USA
    Arthritis Res Ther 8:102. 2006
    ..The choice of index in clinical practice should ideally be based on practical considerations related to the needs of the rheumatologist in the respective health care setting...
  91. ncbi Effectiveness profiles and dose dependent retention of traditional disease modifying antirheumatic drugs for rheumatoid arthritis. An observational study
    Daniel Aletaha
    Department of Internal Medicine, University of Vienna, Austria
    J Rheumatol 29:1631-8. 2002
    ..To determine the fate of traditional disease modifying antirheumatic drugs (DMARD) in the longer term, with special respect to dose related effects on drug retention rates, efficacy, and toxicity...
  92. ncbi Laboratory testing in rheumatoid arthritis patients taking disease-modifying antirheumatic drugs: clinical evaluation and cost analysis
    Daniel Aletaha
    University of Vienna, Vienna, Austria
    Arthritis Rheum 47:181-8. 2002
    ..To develop and validate evidence-based recommendations for routine laboratory tests in patients with rheumatoid arthritis (RA) receiving traditional disease-modifying antirheumatic drugs (DMARDs), and to calculate the monitoring costs...
  93. doi Diagnostic and prognostic value of antibodies and soluble biomarkers in undifferentiated peripheral inflammatory arthritis: a systematic review
    Monika Schoels
    2nd Department of Internal Medicine, Hietzing Hospital, Vienna, Austria
    J Rheumatol Suppl 87:20-5. 2011
    ..We reviewed published evidence on the diagnostic and prognostic performance of autoantibodies and soluble biomarkers in UPIA...
  94. ncbi Minimal disease activity for rheumatoid arthritis: a preliminary definition
    George A Wells
    Department of Epidemiology and Community Medicine, University of Ottawa, Ottawa, Ontario, Canada
    J Rheumatol 32:2016-24. 2005
    ..This set of 2 definitions gained approval of 73% of the attendees. These (and other) definitions will now be subject to further validation in other databases...
  95. ncbi The American College of Rheumatology N (ACR-N) debate: going back into the middle of the tunnel? Comment on the articles by Siegel and Zhen and by Boers
    Daniel Aletaha
    Arthritis Rheum 54:377-8; author reply 378. 2006